{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T02:52:01Z","timestamp":1769309521885,"version":"3.49.0"},"reference-count":19,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,4,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>This article has a companion Counterpoint by Moskowitz.<\/jats:p>","DOI":"10.1182\/bloodadvances.2017011122","type":"journal-article","created":{"date-parts":[[2018,4,10]],"date-time":"2018-04-10T16:00:14Z","timestamp":1523376014000},"page":"817-820","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":12,"title":["Should all patients with Hodgkin lymphoma who relapse after autologous SCT be considered for allogeneic SCT?"],"prefix":"10.1182","volume":"2","author":[{"given":"Karl S.","family":"Peggs","sequence":"first","affiliation":[{"name":"University College London Cancer Institute, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2018,4,10]]},"reference":[{"issue":"11","key":"2019111616175019800_B1","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.3109\/10428194.2013.798868","article-title":"Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant","volume":"54","author":"Arai","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"9475","key":"2019111616175019800_B2","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1016\/S0140-6736(05)66659-7","article-title":"Clinical evidence of a graft-versus-Hodgkin\u2019s-lymphoma effect after reduced-intensity allogeneic transplantation","volume":"365","author":"Peggs","year":"2005","journal-title":"Lancet"},{"issue":"8","key":"2019111616175019800_B3","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1200\/JCO.2010.32.1711","article-title":"Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell-depleted allogeneic transplantation for Hodgkin\u2019s lymphoma","volume":"29","author":"Peggs","year":"2011","journal-title":"J Clin Oncol"},{"issue":"7","key":"2019111616175019800_B4","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.bbmt.2016.03.034","article-title":"Impact of pretransplantation (18)F-fluorodeoxyglucose-positron emission tomography on survival outcomes after T cell-depleted allogeneic transplantation for Hodgkin lymphoma","volume":"22","author":"Reyal","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"2019111616175019800_B5","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/sj.bmt.1705977","article-title":"Superiority of reduced-intensity allogeneic transplantation over conventional treatment for relapse of Hodgkin\u2019s lymphoma following autologous stem cell transplantation","volume":"41","author":"Thomson","year":"2008","journal-title":"Bone Marrow Transplant"},{"issue":"18","key":"2019111616175019800_B6","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1182\/blood-2009-12-253856","article-title":"Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability","volume":"115","author":"Sarina","year":"2010","journal-title":"Blood"},{"issue":"9","key":"2019111616175019800_B7","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1093\/annonc\/mdt206","article-title":"Identification of prognostic factors predicting outcome in Hodgkin\u2019s lymphoma patients relapsing after autologous stem cell transplantation","volume":"24","author":"Mart\u00ednez","year":"2013","journal-title":"Ann Oncol"},{"issue":"30","key":"2019111616175019800_B8","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1200\/JCO.2017.72.6869","article-title":"Post-transplantation cyclophosphamide-based haploidentical transplantation as alternative to matched sibling or unrelated donor transplantation for Hodgkin lymphoma: a registry study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation","volume":"35","author":"Mart\u00ednez","year":"2017","journal-title":"J Clin Oncol"},{"issue":"12","key":"2019111616175019800_B9","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1182\/blood-2016-02-699850","article-title":"Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma","volume":"128","author":"Chen","year":"2016","journal-title":"Blood"},{"issue":"1","key":"2019111616175019800_B10","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1756-8722-7-24","article-title":"Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies","volume":"7","author":"Bartlett","year":"2014","journal-title":"J Hematol Oncol"},{"issue":"5","key":"2019111616175019800_B11","doi-asserted-by":"crossref","first-page":"608","DOI":"10.6004\/jnccn.2017.0064","article-title":"Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology","volume":"15","author":"Hoppe","year":"2017","journal-title":"J Natl Compr Canc Netw"},{"issue":"6","key":"2019111616175019800_B12","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.bbmt.2015.02.022","article-title":"Role of cytotoxic therapy with hematopoietic cell transplantation in the treatment of Hodgkin lymphoma: guidelines from the American Society for Blood and Marrow Transplantation","volume":"21","author":"Perales","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"2019111616175019800_B13","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1016\/j.bbmt.2014.06.037","article-title":"Brentuximab vedotin is associated with improved progression-free survival after allogeneic transplantation for Hodgkin lymphoma","volume":"20","author":"Chen","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"2019111616175019800_B14","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin\u2019s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol"},{"issue":"31","key":"2019111616175019800_B15","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1200\/JCO.2016.67.3467","article-title":"Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure","volume":"34","author":"Armand","year":"2016","journal-title":"J Clin Oncol"},{"issue":"19","key":"2019111616175019800_B16","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J Clin Oncol"},{"issue":"10","key":"2019111616175019800_B17","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1182\/blood-2016-09-738385","article-title":"Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed\/refractory lymphoma","volume":"129","author":"Merryman","year":"2017","journal-title":"Blood"},{"issue":"18","key":"2019111616175019800_B18","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1182\/blood-2016-11-749556","article-title":"Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma","volume":"129","author":"Herbaux","year":"2017","journal-title":"Blood"},{"issue":"1","key":"2019111616175019800_B19","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/j.1365-2141.2007.06759.x","article-title":"Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes","volume":"139","author":"Peggs","year":"2007","journal-title":"Br J Haematol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/2\/7\/817\/880532\/advances011122.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/2\/7\/817\/880532\/advances011122.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,16]],"date-time":"2019-11-16T21:17:54Z","timestamp":1573939074000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/2\/7\/817\/15809\/Should-all-patients-with-Hodgkin-lymphoma-who"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,10]]},"references-count":19,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,4,10]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2017011122","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,10]]}}}